First rival triggers price cut for $70M drug

There have been eight additions to the PBS this month, with Korean biosimilar maker Celltrion Healthcare picking up three reimbursements. The standout addition is Avtozma, which marks the first biosimilar of Roche’s IL6-inhibitor Actemra.

To see the whole article please log in.

Tiffany Walker

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here